title: Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
abstract: OBJECTIVE
  To compare the efficacy and safety of finasteride 5 mg in older (65 years old or older) versus younger (45 to younger than 65 years old) men with benign prostatic hyperplasia (BPH).
  
  
  METHODS
  The Proscar Long-Term Efficacy and Safety Study (PLESS) was a 4-year, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of finasteride 5 mg in 3040 men 45 to 78 years old with symptomatic BPH, enlarged prostates, and no evidence of prostate cancer. The endpoints included urinary symptoms, prostate volume, occurrence of acute urinary retention and/or BPH-related surgery, and safety.
  
  
  RESULTS
  In both age cohorts, finasteride treatment led to a 51% reduction (P <0.001) in the relative risk for acute urinary retention and/or BPH-related surgery, a significant (P <0.001) and durable improvement in symptom score, and a significant (P <0.001) and sustained reduction in prostate volume. Within each age cohort, no significant differences were found between the placebo and finasteride-treated patients in the incidence of cardiovascular adverse events. Significant differences were evident between the placebo and finasteride groups in the incidence of the typical, known, drug-related adverse events, but no specific differences were associated with age. No drug interactions of clinical importance were observed in the finasteride-treated patients.
  
  
  CONCLUSIONS
  The present analysis from PLESS demonstrates that in both older (65 years old or older) and younger men with symptomatic BPH and enlarged prostates, finasteride is highly effective in improving symptoms and reducing prostate volume in many men and in reducing the risk of acute urinary retention and BPH-related surgery. In addition, the safety profile of finasteride in both older and younger men is similar and no drug interactions of clinical importance were observed.
authors.affiliation: Columbia Presbyterian Medical Center, New York, New York 10032, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: H L
authors.initials: HL
authors.lastname: Holtgrewe
authors.forename: R
authors.initials: R
authors.lastname: Bruskewitz
authors.forename: B
authors.initials: B
authors.lastname: Saltzman
authors.forename: D
authors.initials: D
authors.lastname: Mobley
authors.forename: P
authors.initials: P
authors.lastname: Narayan
authors.forename: R H
authors.initials: RH
authors.lastname: Lund
authors.forename: S
authors.initials: S
authors.lastname: Weiner
authors.forename: G
authors.initials: G
authors.lastname: Wells
authors.forename: T J
authors.initials: TJ
authors.lastname: Cook
authors.forename: A
authors.initials: A
authors.lastname: Meehan
authors.forename: J
authors.initials: J
authors.lastname: Waldstreicher
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride